CureVac AG

CureVac AG : German mRNA company with a diversified pipeline; Ph 2a trial ongoing with COVID-19 vaccine candidate, CVnCoV. Global Ph 2/3 trial enrolling approx. 36,500 participants with results expected 1Q21. Three other programs in Ph 1: CV8102 (cutaneous melanoma, adenoidcystic carcinoma, squamous cell cancer of skin, head & neck), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19). Other strategic partnerships include GSK and CRISPR Tx.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase III
Disease Space
Anti-infectives, Antivirals, Autoimmune, COVID-19, Infectious Disease, Oncology, Ophthalmology
Finance
Pre-Revenues
Industry
Biotechnology
Investement Strategy
Under the Radar
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Vaccine
Website:
Profiles:
Address:
Paul-Ehrlich-Straße 15
Tübingen, Baden-Wurttemberg 72076
Germany

Company Participants at 2020 Wall Street "On Tap"

Franz-Werner Haas
CureVac AG, Chief Executive Officer, Chief Operating Officer
Franz-Werner Haas joined CureVac in June 2012. Before joining CureVac, he was Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions. Franz-Werner started his professional career as an assistant to the management of a privately-held holding company before assuming several management positions in the Life Science Industry, including Vice President and General Counsel of LION bioscience and General Counsel of Sirona Dental Systems. He studied law at the University of Saarbruecken, K.U. Leuven and the University of Edinburgh (LL.M.).

Top 10 Holders of CureVac N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Baillie Gifford & Co. 2.85 4,801,656 480.65 13F 12/31/20
Bill & Melinda Gates Foundation 1.86 3,134,780 313.79 13F 12/31/20
T. Rowe Price Associates, Inc. (Investment Management) 0.75 1,267,798 126.91 13F 12/31/20
Geode Capital Management LLC 0.08 129,931 13.01 13F 12/31/20
DWS Investment GmbH 0.07 124,919 12.50 13F 12/31/20
Susquehanna Securities LLC 0.07 121,747 12.19 13F 12/31/20
Samsara Biocapital LLC 0.06 95,318 9.54 13F 12/31/20
D.E. Shaw & Co., Inc. 0.05 83,337 8.34 13F 12/31/20
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 0.04 75,009 7.51 Funds 1/31/21
Jane Street Group LLC 0.04 62,844 6.29 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.